Keyphrases
Placebo
100%
Non-inferiority
100%
Poisson
100%
Non-inferiority Trial
100%
Experimental Therapeutics
100%
Three-arm Trial
100%
Randomized Controlled Trial
66%
Bayesian Methods
66%
Adverse Events
33%
In Cancer
33%
Neurology
33%
Beneficial Effects
33%
Multiple Sclerosis
33%
Treatment Options
33%
Evaluation Criteria
33%
Limited Resources
33%
Clinical Efficacy
33%
Statistical Methods
33%
Lesion Count
33%
Placebo Treatment
33%
Non-inferiority Test
33%
Cancer Clinical Trials
33%
Disease Areas
33%
Sample Size Calculation
33%
Therapeutic Area
33%
Active-controlled Trial
33%
Frequentist
33%
Count Data
33%
Historical Information
33%
Count Outcomes
33%
Cost Burden
33%
Cardiovascular Research
33%
Frequentist Approach
33%
Event Counts
33%
Natural Advantages
33%
Medicine and Dentistry
Arm
100%
Placebo
100%
Noninferiority Trial
100%
Experimental Therapy
75%
Randomized Controlled Trial
50%
Health Care Cost
25%
Adverse Event
25%
Malignant Neoplasm
25%
Disease
25%
Cardiovascular System
25%
Side Effect
25%
Multiple Sclerosis
25%
Dermatology
25%
Neurology
25%
Statistical Analysis
25%
Mathematics
Bayesian
100%
Experimental Treatment
100%
Arm Trial
100%
Superiority
33%
Statistical Method
33%
Count Data
33%
Sample Size Calculation
33%
Frequentist
33%
Frequentist Approach
33%
Pharmacology, Toxicology and Pharmaceutical Science
Placebo
100%
Noninferiority Trial
100%
Randomized Controlled Trial
50%
Adverse Event
25%
Malignant Neoplasm
25%
Disease
25%
Side Effect
25%
Multiple Sclerosis
25%
Neuroscience
Placebo
100%
Randomized Controlled Trial
50%
Multiple Sclerosis
25%